Reported Reactions

Adverse event reports that FDA received

  • Search
  • Watch list

Marinol (dronabinol) adverse event reports that FDA received

Name type
Brand name
Generic name
Dronabinol
Also reported as
Marinol /00003301/, Marinol /00897601/

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on . The data have the reports that FDA received through .

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on .

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From July 2004 to July 2025, FDA received 452 adverse event reports that name Marinol. In these reports the drug is a suspect or interacting product.

In the same period, 2,955 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 1 report in the 12 months to June 2026 and 4 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Marinol is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

  • In April to June 2026, FDA received 0 reports that name Marinol.
  • In January to March 2026, FDA received 0.
  • In April to June 2025, FDA received 1.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updatesFeed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 42 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

This list is partial.

It covers 400 of the 452 reports (88.5%).

The site keeps reaction terms only for years in which the drug has 12 or more reports.

So a count in the table can be lower than the count of FDA.

The table shows all 42 terms.

Reaction terms in the reports that name Marinol, most reports first
Reaction term (MedDRA) and plain meaningReportsShare of the 452 reports
Nauseafeeling sick4910.8%
Vomitingbeing sick4510%
Off label useused for a purpose or in a way not on the label439.5%
Weight decreasedweight loss327.1%
Deaththe patient died; cause not stated by this term276%
Decreased appetitereduced appetite214.6%
Painpain, site not specified214.6%
Confusional stateconfusion204.4%
Astheniaweakness or lack of energy184%
Drug ineffectivethe medicine did not work as expected163.5%
Abdominal painstomach or belly pain143.1%
Dehydration143.1%
Dizzinesslight-headedness or unsteadiness122.7%
Falla fall122.7%
Diarrhoealoose or frequent stools102.2%
Malaisegeneral feeling of being unwell102.2%
Seizurea fit or convulsion102.2%
Therapeutic response unexpected92%
Abdominal pain upperupper stomach pain81.8%
Drug interactionan interaction between medicines81.8%
Drug screen positive81.8%
Fatiguetiredness81.8%
Feeling abnormalfeeling odd or not right71.5%
Hypophagia71.5%
Infectionan infection, type not specified71.5%
Insomniadifficulty sleeping71.5%
Pancreatitisinflammation of the pancreas71.5%
Back pain61.3%
Chest pain61.3%
Drug dose omissiona dose was missed61.3%
Hallucinationseeing or hearing things that are not there61.3%
Headachehead pain61.3%
Hyponatraemialow blood sodium61.3%
Incorrect dose administeredthe wrong dose was given61.3%
Pneumonialung infection61.3%
Somnolencedrowsiness61.3%
Suicidal ideationthoughts of suicide61.3%
Tremorshaking61.3%
Convulsion51.1%
Drug dependencedependence on a medicine51.1%
Dyskinesiainvoluntary movements51.1%
Weight increasedweight gain51.1%

Download all 42 terms of Marinol (CSV)

The counts add to more than 452 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Dronabinol with a page, in the order generic names, brand names, names as reported
NameName typeReports
DronabinolGeneric name1,417
Marinol (this page)Brand name452

Sum of the separately reported names: 1,869. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Marinol, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA fileReportsSeriousDeathLife-threateningHospitalization (initial or prolonged)Disability or Permanent DamageCongenital Anomaly/Birth DefectOther Serious (Important Medical Events)Not serious
2004141420130000
2005440031000
20061191240042
200714132172031
2008552010020
2009551130020
2010761030021
20111682050048
20121381030055
2013411640710925
20144722411600625
20154922110900827
2016362150800815
201739321001100177
201848303016101518
201931171010001014
202032400300228
2021241900170075
2022500000005
2023200000002
2024530020032
2025320000021
2026111000010

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition

Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on .

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Marinol, by the year in which FDA received them
050100200420082012201620202024
Show the figures of the chart as a table
Reports that name Marinol, by the year in which FDA received them
YearReports
200411
20057
200611
200713
20086
20095
20107
20117
201224
201340
201451
201544
201638
201740
201845
201931
202038
202122
20224
20232
20244
20252
Reports that name Marinol, by month, five years to June 2026
051020222023202420252026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Marinol
AgeReportsShareShare as a bar
Under 210.2%
2 to 1100%
12 to 1751.1%
18 to 447115.7%
45 to 6410423%
65 to 74347.5%
75 and over255.5%
Age not given21246.9%
Sex of the patient in the reports that name Marinol
SexReportsShareShare as a bar
Female21748%
Male20745.8%
Unknown or not given286.2%
Type of reporter in the reports that name Marinol
ReporterReportsShareShare as a bar
Physician9420.8%
Pharmacist337.3%
Other health professional6013.3%
Lawyer20.4%
Consumer or non-health professional24253.5%
Not given214.6%

Age and sex are as the report gives them. The reporter is the primary source in the report. 89.4% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Marinol record
Indication as recorded (MedDRA)ReportsShare
Nausea429.3%
Decreased appetite286.2%
Pain224.9%
Increased appetite173.8%
Ill-defined disorder71.5%
Appetite disorder61.3%

The reporter fills in the indication, and the field is often empty. Each share is of all 452 reports.

Pages near this one

These links are for navigation. No count selected them.

Official pages

The site checked these addresses on . The links open in a new tab.

Cite this page

Reported Reactions. Marinol: adverse event reports that FDA received. https://reportedreactions.com/drug/marinol/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of . Reports received through .

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Marinol as a suspect or interacting product. The 2,955 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Marinol was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.

Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of . The site read the page on .

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Marinol?

No. It is a count of what people reported to FDA: 452 reports from July 2004 to July 2025. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Consumer or non-health professional (53.5%), physician (20.8%) and other health professional (13.3%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.

Source: openFDA, Drug Adverse Event Overview. The site read the page on .

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.